FDA approves daclizumab

Today on Barts MS Blog

"The FDA has approved daclizumab (Zinbryta) for the treatment of relapsing forms of MS. However, the FDA have recommended it be used second or third line, presumably because of its safety profile and need for monitoring. "

It’s always a good thing when a new drug comes to the market. Even if it does still need a load of safety testing etc.